-+ 0.00%
-+ 0.00%
-+ 0.00%

Edding Genor Signs Deal With Taizhou EOC to Produce Two Drugs

PUBT·11/17/2026 13:48:31
Listen to the news
Edding Genor Signs Deal With Taizhou EOC to Produce Two Drugs
  • Edding Genor's subsidiary Eddingpharm Zhuhai signed a technology transfer and commercial production agreement with Taizhou EOC on November 17, 2026.
  • The agreement covers Rujianing and Mulpleta through December 31, 2028, with automatic three-year renewals subject to listing requirements.
  • Technology transfer fees total RMB 14.6 million, including tax, with 30% payable upon signing and the remainder tied to milestones.
  • Taizhou EOC will buy production equipment for up to RMB 11 million through product-payment deductions; Eddingpharm Zhuhai retains ownership until fully paid.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261117-12416455), on November 17, 2026, and is solely responsible for the information contained therein.